Blog

The February 2015 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. There is only one ...

[:content [\1 \3 \space \M \a \r \c \h \  \2 \0 \1 \4 \space \- \  \T \h \e \space \S \M \C \space \a \d \v \i \c \e \space \f \o \r \space \M \a \r \c \h \space \2 \0 \1 \4 \space \h \a \s \space \b \e \e \n \space \e \n \t \e \r \e \d \space \i \n \t \o \space \M \A \E \S \T \r \O \space \S \c \o \t \l \a \n \d \. " ..."]]

Novartis Pharmaceuticals Canada Inc. announced today that Health Canada has approved the use of Xolair (omalizumab) as a treatment of adults ...

An update to the Submission Deadlines and Projected Effective Dates, which now includes the application deadlines for all six price change ...

CADTH has received notice of a pending submission from Alexion for Strensiq (asfotase alfa) for patients with hypophosphatasia.  For information about ...

[:content [\1 \3 \space \J \a \n \u \a \r \y \space \2 \0 \1 \4 \space \- \  \P \H \A \R \M \A \C \space \i \s \space \p \l \e \a \s \e \d \space \t \o \space \a \n \n \o \u \n \c \e \space \t \h \e \space \a \p \p \r \o \v \a \l \space \o \f \space \p \r \o \p \o \s \a \l \s \space \t \o \space \a \m \e \n \d \space \a \c \c \e \s \s \space \t \o \space \s \u \g \a \m \m \a \d \e \x \space \a \n \d \space \a \t \o \m \o \x \e \t \i \n \e \space \a \n \d " ..."]]

[:content (" ...")]

[:content [\1 \3 \space \D \e \c \e \m \b \e \r \space \2 \0 \1 \3 \space \- \space \G \e \n \z \y \m \e \  \a \n \n \o \u \n \c \e \d \space \t \o \d \a \y \space \t \h \a \t \space \H \e \a \l \t \h \space \C \a \n \a \d \a \space \h \a \s \space \a \p \p \r \o \v \e \d \space \L \e \m \t \r \a \d \a \space \( \a \l \e \m \t \u \z \u \m \a \b \) \space \f \o \r \space \t \h \e \space \m \a \n \a \g \e \m \e \n \t \space \o \f \space \a \d \u \l \t \space \p \a \t \i \e \n \t \s \space \w \i \t \h " ..."]]

The agenda for the 28 May 2014 Transparency Commission meeting is now available.  The Commission will examine the following health ...

NICE has recommended lubiprostone (Amitiza, Sucampo Pharma Europe) as a treatment option for chronic idiopathic constipation in adults. ...

The Schedule of Pharmaceutical Benefits is provided in a variety of formats including PDF versions of both the monthly schedule and ...

Danish drugmaker Novo Nordisk, the world's biggest insulin producer, said on Wednesday it had decided to launch its diabetes drug ...

PHARMAC is pleased to announce a decision to list tobramycin powder and widen access to clarithromycin infusion. In summary, the ...

 8 July 2014 - Pharmaceutical industry leaders are calling for an alternative reimbursement model for antibiotics in the UK sooner ...